Select Language
CD40 Ligand
CD40 Ligand Overview
| English Name | CD40 ligand | Approved Drugs | 0 |
| Drugs in Clinical Trials | 14 | Target Synonym | CD154 Antigen，HCD40L，CD154，TNFSF5，CD40L，CD40 ligand， soluble form，CD40 ligand， membrane form，Tumor necrosis factor ligand superfamily member 5，T-cell antigen Gp39，CD40-L，CD40LG，TNF-Related Activation Protein，Tumor Necrosis Factor (Ligand) Superfamily Member 5，T-B Cell-Activating Molecule，T-BAM，HIGM1，Gp39，IMD3，IGM，CD40 Ligand，CD40 Antigen Ligand，TRAP，Tumor Necrosis Factor (Ligand) Superfamily， Member 5 (Hyper-IgM Syndrome)，Hyper-IgM Syndrome，sCD40L |
| Highest Development Stage | Phase 3 Clinical | ||
| English Name | CD40 ligand |
| Target Synonym | CD154 Antigen，HCD40L，CD154，TNFSF5，CD40L，CD40 ligand， soluble form，CD40 ligand， membrane form，Tumor necrosis factor ligand superfamily member 5，T-cell antigen Gp39，CD40-L，CD40LG，TNF-Related Activation Protein，Tumor Necrosis Factor (Ligand) Superfamily Member 5，T-B Cell-Activating Molecule，T-BAM，HIGM1，Gp39，IMD3，IGM，CD40 Ligand，CD40 Antigen Ligand，TRAP，Tumor Necrosis Factor (Ligand) Superfamily， Member 5 (Hyper-IgM Syndrome)，Hyper-IgM Syndrome，sCD40L |
| Approved Drugs | 0 |
| Drugs in Clinical Trials | 14 |
| Highest Development Stage | Phase 3 Clinical |
CD40 Ligand Product List
- Product Category
Protein (11)Cell (1)
- Product Status
Launched (12)
- Species
Mouse (4)Human / Rhesus macaque (1)Human (6)Rabbit (1)
- Tag
His Tag (1)Fc Tag (3)Mouse IgG Fc Tag (1)His Tag & Flag Tag (3)His Tag & Fc Tag & Avi Tag (1)- (1)His Tag & Avi Tag (1)Avi Tag & Fc Tag (1)
- Conjugate
Unconjugated (8)Biotin-labeled (3)- (1)
Add to Cart
Total: 12
- 1
- 2
CD40 Ligand Background
The protein encoded by this gene is expressed on the surface of T cells. It regulates B cell function by engaging CD40 on the B cell surface. A defect in this gene results in an inability to undergo immunoglobulin class switch and is associated with hyper-IgM syndrome. [provided by RefSeq, Jul 2008]
CD40 Ligand Synonyms
CD40LG,CD154,CD40L,HIGM1,IGM,IMD3,T-BAM,TNFSF5,TRAP,gp39
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Dapirolizumab pegol | Anti-CD40L-Fab; Anti-CD40L-Fab-PEG; CDP-7657; CD40L - Fab; BIIB-133 | Phase 3 Clinical | Biogen Inc, Ucb | Autoimmune Diseases; Connective Tissue Diseases; Immune System Diseases; Lupus Erythematosus, Systemic; Skin and Connective Tissue Diseases | Details |
| Dazodalibep | VIB-4920; MEDI-4920; HZN-4920(Horizon Therapeutics); UNII-HN5US76BWF; WHO-11399 | Phase 3 Clinical | Horizon Therapeutics PLC, Medimmune Llc | Arthritis, Rheumatoid; Graft Rejection; Lupus Nephritis; Rejection of renal transplantation; Sjogren's Syndrome; Sjogren-Larsson Syndrome | Details |
| Frexalimab | INX-021; SAR-441344 | Phase 3 Clinical | Immunext Inc | Diabetes Mellitus, Type 1; Glomerulonephritis; Glomerulosclerosis, Focal Segmental; Lupus Erythematosus, Systemic; Multiple Sclerosis; Nephrosis; Rejection of renal transplantation; Sjogren's Syndrome; Sjogren-Larsson Syndrome | Details |
| Anti-CD40L antibody (Bristol-Myers Squibb) | Phase 2 Clinical | Bristol-Myers Squibb Company | Immunologic Deficiency Syndromes | Details | |
| Tegoprubart | AT-1501 | Phase 2 Clinical | Als Therapy Development Institute | Amyotrophic Lateral Sclerosis; Diabetes Mellitus, Type 1; Glomerulonephritis, IGA; Rejection of renal transplantation | Details |
| Delolimogene mupadenorepvec | LOAd-703 | Phase 2 Clinical | Lokon Pharma, Uppsala University | Biliary Tract Neoplasms; Colorectal Neoplasms; Melanoma; Ovarian Neoplasms; Pancreatic Neoplasms | Details |
| TNX-1500 | TNX-1500 | Phase 2 Clinical | Tonix Pharmaceuticals Holding Corp | Autoimmune Diseases; Autoimmune Diseases of the Nervous System; Rejection of renal transplantation; Rejection of organ transplantation | Details |
| Base-edited hematopoietic stem and progenitor cells therapy (NIAID) | Phase 2 Clinical | National Institute Of Allergy And Infectious Diseases (Niaid) | Hyper-IgM Immunodeficiency Syndrome, Type 1 | Details | |
| CD40 ligand expressing MSLN-CAR T cells | Phase 2 Clinical | Pla General Hospital | Solid tumours | Details | |
| Letolizumab | BMS-986004; BMS2h-572-633-CT-L2 | Phase 1 Clinical | Bristol-Myers Squibb Company | Graft vs Host Disease; Purpura, Thrombocytopenic, Idiopathic | Details |
| MEM-288 | MEM-288 | Phase 1 Clinical | Memgen | Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Solid tumours; Triple Negative Breast Neoplasms | Details |
| IBI355 | IBI-355 | Phase 1 Clinical | Lupus Erythematosus, Systemic; Sjogren's Syndrome | Details | |
| CD40L-augmented Tumor Infiltrating Lymphocytes (H Lee Moffitt Cancer Center & Research Institute) | Phase 1 Clinical | H Lee Moffitt Cancer Center & Research Institute | Carcinoma, Non-Small-Cell Lung | Details | |
| Lu-AG22515 | APB-A1; Lu-AG22515 | Phase 1 Clinical | AprilBio Co Ltd | Graves Ophthalmopathy; Neuromyelitis Optica | Details |
- Overview
- Product List
- Clinical Drug Information
Share to:
Online Message
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland